Skip to main content

Table 1 Patients and tumours characteristics (n = 53)

From: Evaluation of response to conventional chemotherapy and radiotherapy by perfusion computed tomography in non-small cell lung cancer (NSCLC)

Smoking 48 (90.6)
Family history of lung cancer 15 (28.3)
Personal history of cancer 3 (5.7)
Comorbidities 17 (32.1)
Presentation
 Incidental finding 10 (18.9)
 Solitary pulmonary nodule 1 (1.9)
 Cough 50 (40.3)
 Dyspnoea 18 (34.0)
 Pain 13 (24.5)
 Haemoptysis 12 (22.6)
 Constitutional syndrome 27 (50.9)
Histology
 Adenocarcinoma 28 (52.8)
 Epidermoid 16 (30.2)
 Undifferentiated 5 (9.4)
 Large cell 3 (5.7)
 Neuroendocrine 1 (1.9)
Treatment
 CCT with platinum 46 (86.8)
 CCT and RT 7 (13.2)
Stage
 IIB 3 (5.7)
 IIIA 7 (13.2)
 IIIB 11 (20.8)
 IV 32 (60.4)
RECIST-1.1 diameter (mm) 59 ± 22 (21–115)
Volume (cc) 107 ± 137 (1–605)
Time from baseline PCT to CCT start (days) 29.37 ± 15.8 (8–82)
Time from CCT start to control PCT (days) 63.9 ± 28.1 (42–138)
  1. Data are given as absolute frequencies with percentages in parentheses or means ± standard deviations with ranges in parentheses. CCT Conventional chemotherapy, PCT Perfusion computed tomography, RECIST Response evaluation criteria in solid tumours, RT Radiation therapy